Antiviral T-cell responses and therapy in chronic hepatitis B.

[1]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[2]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[3]  Y. Çelik,et al.  Comparison of 12-Month Courses of Interferon-α-2b–Lamivudine Combination Therapy and Interferon-α-2b Monotherapy among Patients with Untreated Chronic Hepatitis B , 2003 .

[4]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[5]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[6]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[7]  J. Trojan,et al.  Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. , 2002, Vaccine.

[8]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[9]  Mark George Thomas,et al.  Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. , 2002, Gastroenterology.

[10]  S. Zeuzem,et al.  Interleukin-12 in the treatment of chronic hepatitis B and C. , 2001, Antiviral research.

[11]  J. Prieto,et al.  T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. , 2001, Journal of Hepatology.

[12]  C. Bréchot,et al.  Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. , 2001, Journal of hepatology.

[13]  G. Ogg,et al.  Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.

[14]  Y. Liaw.  Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. , 2001, Antiviral chemistry & chemotherapy.

[15]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[16]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[17]  Antonio Bertoletti,et al.  The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. , 2000 .

[18]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[19]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[20]  A. Sette,et al.  A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus , 1999, Hepatology.

[21]  C. Bréchot,et al.  Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. , 1999, The Journal of infectious diseases.

[22]  R. Liang,et al.  Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. , 1998, The Journal of infectious diseases.

[23]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[24]  R. D. de Man,et al.  Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. , 1998, Journal of hepatology.

[25]  G. Fattovich,et al.  Double‐blind, randomized controlled trial of interleukin‐2 treatment of chronic hepatitis B , 1998, Journal of medical virology.

[26]  Koziel Mj.  The immunopathogenesis of HBV infection. , 1998 .

[27]  J. Prieto,et al.  Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. , 1997, Journal of hepatology.

[28]  F. Chisari,et al.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response , 1996, Nature Medicine.

[29]  D. Tyrrell,et al.  Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.

[30]  F. Chisari,et al.  Long-lasting memory T cell responses following self-limited acute hepatitis B. , 1996, The Journal of clinical investigation.

[31]  F. Chisari.  Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. , 1996, Current topics in microbiology and immunology.

[32]  Y. Ilan,et al.  Immunization against hepatitis B through adoptive transfer of immunity. , 1995, Intervirology.

[33]  E. O’Neill,et al.  T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6 , 1994, The Journal of experimental medicine.

[34]  F. Chisari,et al.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis , 1993, The Journal of experimental medicine.

[35]  C. Tzeng,et al.  Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. , 1993, International journal of hematology.

[36]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[37]  J. Price,et al.  Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? , 1990, Proceedings of the National Academy of Sciences of the United States of America.